Exclusive Summary

• First-in-Class Bispecific Mechanism: As a pioneering bispecific antibody simultaneously targeting TL1A and IL-6R, it offers a revolutionary therapeutic strategy for multiple autoimmune diseases through a potentially synergistic mechanism.
• Potential for Superior Clinical Efficacy: By concurrently blocking two key pathways (Th17 and Th1), UB343 is poised to surpass the efficacy of single-target drugs, including the highly anticipated TL1A monoclonals, and address non-response and resistance issues of current therapies.
• "Pipeline-in-a-Product" with Blockbuster Potential: The dual-target mechanism holds strong scientific rationale across multiple high-value indications like IBD, Uveitis, MS, and SLE, representing immense commercial value as a "pipeline-in-a-product."
• Strong Preclinical Proof-of-Concept: In vitro data demonstrates UB343's picomolar (pM) high affinity for both human TL1A and IL-6R, along with potent inhibition of both signaling pathways at the cellular level, providing a robust data package for rapid advancement into clinical development.

Asset Materials

Contact Us for Full Materials